A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Sikander Ailawadhi, Kevin R. Kelly, Robert A. Vescio, Sundar Jagannath, Jeffrey Wolf, Mecide Gharibo, Taimur Sher, Leyla Bojanini, Maurice Kirby, Asher Chanan-Khan

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the single agent describes the maximum tolerated dose, safety, and initial efficacy to aid future drug development.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number1
DOIs
StatePublished - Jan 2019

Keywords

  • Antibody-drug conjugate
  • Drug-development
  • Efficacy
  • Immunotherapy
  • Monoclonal antibody

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma'. Together they form a unique fingerprint.

Cite this